Search

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

EHA2024 Hybrid Congress

Thank you all for joining us in Madrid for the 29th European Hematology Association Congress!

The EHA2024 Congress platform is now closed. You may browse selected content through the EHA Library, EHA Open access library.

Read more

Last chance: special EAPM2017 registration offer for EHA members

EAMP2017 will take place in Belfast, Ireland, from 27-29 November 2017.  The European Alliance for Personalised Medicine (EAPM), launched in March 2012, brings together European healthcare experts and patient advocates involved with major chronic diseases.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

EHA-SWG Scientific Meeting "Patient-centered Geriatric Hematology"

EHA & the EHA Scientific Working Group on Hematology and Aging are happy to announce their recent collaboration in organizing a virtual meeting program providing delegates with the latest insights in the field of geriatric hematology, presented by leading hematologists.

Read more

Splenic marginal zone lymphoma study update, February 2024

A project update from Dr Ahmed Ludvigsen Al-Mashhadi. I am truly grateful for this opportunity provided by EHA, and for EHA's effort in advancing research in a field that may otherwise be very difficult to explore.

Read more

Addressing the bureaucracy challenge

EHA has recently brought key stakeholders around the table to discuss bureaucratic obstacles in clinical research.

Read more